Investing.comCodex · 实盘不做把握 5/10不做原因:风险收益比不佳
北京时间·🕒 发布 04:13:01·⟳ 抓取 04:14:22 +1m21s·⚡ 决策 08-27 13:27:28 +9h13m·61.4 天前
安捷伦三季度业绩超预期并上调全年指引，但盘后已重定价且增量质量一般
事件方向明确偏正面，但增量幅度相对安捷伦约438亿美元市值和近期涨幅不够大，盘后已反映主要惊喜；在未能完成强制stock_tools行情与event_study校验的情况下，不给新仓ENTER。
📄 原文Investing.com↗ 原文
Agilent Technologies beats estimates, raises guidance on strong demand
Wall Street sees muted session amid mixed PCE data, caution ahead of Nvidia test Investing.com -- Agilent Technologies…
不做 Agilent Technologies Inc.（A.US）
业绩方向偏利好但全年指引增量不大且含一次性关税退款，盘后已涨约3.8%至接近52周高位；缺少完成stock_tools真实行情和event_study后的正期望依据，不追多。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
安捷伦FY2026三季度收入和EPS均超预期，并上调全年收入与EPS指引，说明生命科学和诊断需求在改善；但EPS超预期中包含一次性关税退款，全年EPS中值6.195美元相对6.06美元一致预期增量约2.2%，收入指引中值75.0亿美元相对74.5亿美元一致预期增量约0.7%，盘后股价已涨约3.8%至161美元、接近52周高位，短线追多的预期差和安全边际不足。
消息传播链
- 公司盘后发布FY2026三季度财报，披露收入、EPS、利润率和全年指引上调。
- 媒体报道EPS和收入均超FactSet预期，并给出Q4与全年新指引。
- 盘后报价显示A.US约161.00美元，较155.05美元收盘价上涨约3.84%。市场反应:盘后上涨约3.8%。
关键理由
- 正面事实是收入18.8亿美元和非GAAP EPS 1.62美元均高于一致预期，且公司上调全年收入和EPS指引。
- 量级上，FY2026收入指引中值较一致预期约多0.5亿美元，约占全年收入基数0.7%；EPS中值较一致预期约高0.135美元，约占预期2.2%，对438亿美元市值的短线弹性有限。
- 各业务均增长，LDG收入同比增长11%至7.46亿美元，说明终端需求改善不是单一小项。
主要风险
- 调整后EPS中0.06美元来自关税退款，利润质量折扣明显，且公司说明Q4指引不含未来关税退款收益。
- 股价8月以来和近三个月已大幅上行，盘后又涨至约161美元，接近52周高位，存在财报利好兑现后的回落风险。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-08-26 · 影响 weakens
公司披露Q3非GAAP EPS含0.06美元关税退款收益，且Q4指引不含未来关税退款收益，利润质量削弱追多强度。
检索:Agilent Q3 2026 tariff refund EPS benefit guidance after hours valuation risk 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-08-26 · 影响 weakens
盘后约161美元已接近或略高于近期52周高位，事件前一个月和三个月已有明显上行，追高性价比下降。
检索:Agilent stock price August 2026 52 week high before earnings 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-08-26 · 影响 invalidates
当前事件为业绩和指引双超预期，未发现足以反手做空的公司级新增净利空。
检索:Agilent Q3 2026 earnings beat raises guidance short thesis 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例确认事件方向为正，但因缺少真实事件研究和本次盘后已涨，最终压低为AVOID。
方向:同公司先例支持财报beat-and-raise方向偏正面，但样本不足以支撑追高下单。
涨幅量级:缺少高相似且已通过event_study计量的样本，不能用先例设定可靠TP/SL。
形态:现有可查样本显示盘后可能快速反映利好，未能验证次日以后是否继续扩散。
历史先例(按相似度)
- 相似度 7/10 A.US 2026-05-27 FY2026 Q2收入18.3亿美元、EPS 1.49美元并上调全年指引，Investing.com称盘后涨约8.3%。 原文 ↗
事件后 +1日 +16.9% · +2日 +17.0% · +3日 +17.4% · +4日 +16.6% · +5日 +18.6%
⚠相位不对齐(post!=target_unknown) — 该行涨幅别用来定止盈止损
相似度依据:同一公司、同一财报超预期并上调全年指引机制，但无法调用event_study取得真实1/3/5日超额收益。
经验:安捷伦上一季度类似 beat-and-raise 可引发明显盘后反应，但本次盘后涨幅已先行兑现一部分。 - 相似度 5/10 A.US 2026-02-25 FY2026 Q1收入18.0亿美元，非GAAP EPS 1.36美元，全年EPS指引因汇率小幅上调。 原文 ↗
事件后 +1日 -3.0% · +2日 -2.7% · +3日 -5.2% · +4日 -4.5% · +5日 -3.4%
⚠相位不对齐(post!=target_unknown) — 该行涨幅别用来定止盈止损
相似度依据:同一公司财报与全年指引更新，但Q1为小幅错失预期且机制弱于当前。
经验:只有指引小幅上修而当季质量一般时，盘后反应可较温和。
原文全文
展开原文 · 1,967 字
Wall Street sees muted session amid mixed PCE data, caution ahead of Nvidia test
Investing.com -- Agilent Technologies Inc (NYSE:A) reported third-quarter results that exceeded analyst expectations and raised its full-year guidance, driven by improving end markets and strong product demand. Shares rose 3% in after-hours trading Wednesday.
The analytical and clinical laboratory technology company posted adjusted earnings per share of $1.62 for the third quarter ended July 31, 2026, beating the analyst consensus of $1.49 by $0.13. Revenue reached $1.88 billion, up 8.1% YoY and above the $1.84 billion estimate. The adjusted EPS included a $0.06 benefit from tariff refunds. Analyze the report by upgrading to InvestingPro - get 55% off today Agilent raised its fiscal 2026 adjusted EPS guidance to a range of $6.18 to $6.21, with a midpoint of $6.195 that exceeds the analyst consensus of $6.06. The company also increased its full-year revenue outlook to $7.49 billion to $7.51 billion, representing growth of 7.8% to 8.1%, up 65 basis points at the midpoint from prior guidance.
For the fourth quarter, Agilent expects revenue of $1.98 billion to $2.0 billion and adjusted EPS of $1.71 to $1.74. The revenue guidance midpoint of $1.99 billion represents growth of approximately 6.9% YoY on a reported basis.
"Agilent's exceptional third-quarter performance reflects the sustained momentum created by our strategy, our execution discipline, and the compounding impact of the Ignite Operating System," said CEO Padraig McDonnell. "We are seeing improving end markets, stronger demand in key regions, and excellent customer response to our innovative product launches."
The company's adjusted operating margin expanded 320 basis points YoY to 28.3%, which included a 110 basis point benefit from tariff refunds. All three business segments posted revenue growth, with the Life Sciences and Diagnostics Markets Group leading at 11% reported growth to $746 million.
Investing.com -- Agilent Technologies Inc (NYSE:A) reported third-quarter results that exceeded analyst expectations and raised its full-year guidance, driven by improving end markets and strong product demand. Shares rose 3% in after-hours trading Wednesday.
The analytical and clinical laboratory technology company posted adjusted earnings per share of $1.62 for the third quarter ended July 31, 2026, beating the analyst consensus of $1.49 by $0.13. Revenue reached $1.88 billion, up 8.1% YoY and above the $1.84 billion estimate. The adjusted EPS included a $0.06 benefit from tariff refunds. Analyze the report by upgrading to InvestingPro - get 55% off today Agilent raised its fiscal 2026 adjusted EPS guidance to a range of $6.18 to $6.21, with a midpoint of $6.195 that exceeds the analyst consensus of $6.06. The company also increased its full-year revenue outlook to $7.49 billion to $7.51 billion, representing growth of 7.8% to 8.1%, up 65 basis points at the midpoint from prior guidance.
For the fourth quarter, Agilent expects revenue of $1.98 billion to $2.0 billion and adjusted EPS of $1.71 to $1.74. The revenue guidance midpoint of $1.99 billion represents growth of approximately 6.9% YoY on a reported basis.
"Agilent's exceptional third-quarter performance reflects the sustained momentum created by our strategy, our execution discipline, and the compounding impact of the Ignite Operating System," said CEO Padraig McDonnell. "We are seeing improving end markets, stronger demand in key regions, and excellent customer response to our innovative product launches."
The company's adjusted operating margin expanded 320 basis points YoY to 28.3%, which included a 110 basis point benefit from tariff refunds. All three business segments posted revenue growth, with the Life Sciences and Diagnostics Markets Group leading at 11% reported growth to $746 million.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。